Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Stud
about
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Timing and extent of response in colorectal cancer: critical review of current data and implication for future trialsEribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.The ARCAD clinical trials program: an update and invitation.Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.Design Issues in Randomized Clinical Trials of Maintenance Therapies.When progressive disease does not mean treatment failure: reconsidering the criteria for progression.A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patientsMABp1 for the treatment of colorectal cancer.The IR Evolution in Oncology: Tools, Treatments, and Guidelines.Meta-regression of treatments for metastatic colorectal cancer: Quantifying incremental benefit from 2000 to 2012.Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points.Therapeutic strategy in unresectable metastatic colorectal cancer.Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy.An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.Conceptual approaches to metastatic disease.
P2860
Q24658529-2129FAFB-45DE-479E-840B-AE3BD35052EBQ26797292-8163317A-2E7A-4AA4-8B57-5100C003279CQ33583275-D83431D9-CE00-451A-86A1-B513ADBD575DQ35088086-BED9891B-AD07-4DCA-828D-5B8E67B1A31FQ35682543-750DC4F9-AC9E-4A84-B093-F08E2BFA5B95Q35776224-8835E54D-FBAB-431C-A310-E813AA345DF2Q35918612-D47F1E16-B023-4F6D-AAF8-CACCAAAD16ADQ36173497-248E7F1C-9E1C-4D4C-B36F-09959548A7BAQ36848078-4C06EF84-6A3E-411D-B64F-54B41566AA51Q37003248-A2EB689A-402A-4CE6-AF4C-47BA0787E829Q37272489-7ED874FB-E043-425E-B549-DF7BF21142B8Q38686881-6C7628A5-4EDD-492C-B82E-605053A4C729Q38792207-78EC9A67-29B3-4834-9888-29A1AC05B233Q39398894-B15A0A8D-D13E-4457-92C9-D720A11EB013Q41865845-38D98C05-40B0-44CE-A696-EAC2883A3B13Q42000639-CC7F48C1-9F5E-47A7-8BAC-E5F30F83B2F3Q50973552-1E746337-3ED5-42BA-A228-DF68401A3C54Q52602395-90536C9F-B4E8-4D7B-BC83-44105F338BE7Q52842543-D69A2377-AE90-46C8-927A-582CAC660C58
P2860
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Stud
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Alternative end points to eval ...... cerologie Digestive Group Stud
@en
Alternative end points to eval ...... cerologie Digestive Group Stud
@nl
type
label
Alternative end points to eval ...... cerologie Digestive Group Stud
@en
Alternative end points to eval ...... cerologie Digestive Group Stud
@nl
prefLabel
Alternative end points to eval ...... cerologie Digestive Group Stud
@en
Alternative end points to eval ...... cerologie Digestive Group Stud
@nl
P2093
P356
P1476
Alternative end points to eval ...... cerologie Digestive Group Stud
@en
P2093
Aimery de Gramont
Benoist Chibaudel
Carmen J Allegra
Christophe Tournigand
Franck Bonnetain
Marc Buyse
Richard M Goldberg
P304
P356
10.1200/JCO.2011.35.5867
P407
P577
2011-10-03T00:00:00Z